The latest Novartis action to shutdown RNAi research based on:
"... the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move."
http://www.fiercebiotech.com/story/breaking-novartis-slams-brakes-rnai-development-efforts/2014-04-14
This contrasts with the EET and potential Phenomica progress in which:
- The delivery problem has been completely resolved;
- The targeting problem looks like it can be feasibly addressed; and
- The complex RNA payload against gene expression can be replaced with a simple payload against phenotype expression.
Compare the multiple billion$ directed to RNAi programmes - where Phylogica's tens of million$ actually has produced a significantly more effective platform.
Add to My Watchlist
What is My Watchlist?
